EXPLORE AREAS OF INTEREST
- Genomic Medicine
- Hereditary Cancer Risk Assessment
- Reproductive Medicine
- Hearing Loss & Newborn Screening
- Clinical Exome Sequencing
Otogenetics is a Next Generation Sequencing (NGS) laboratory service provider established by two professors from Emory University School of Medicine in 2007 with NIH funding. The company developed and launched a Newborn Screening Hearing Loss Panel sequencing 167 genes associated with Syndromic and Non-Syndromic Hearing Loss. Our test offering now includes Genomic Medicine, Hereditary Cancer Risk Assessment, Expanded Carrier Screening, Pharmacogenomics & Personalized Medicine, Cardiomyopathy, and Whole Exome & RNA Sequencing for precision treatment of tumors, and testing for Rare Diseases. Disease panels are custom designed for both research collaborators and clinical diagnostics.
Test results for genetic diagnoses and risk assessment using NGS technologies resulted in publications in highly reputable biomedical journals including Nature and Nature Medicine; attesting to the high caliber and quality of the gene panel design offered by the company. Otogenetics also assists medical schools in training a new generation of medical students in Precision Medicine.
Publications & Press Releases
US life expectancy varies > 20 years regionally. Access to quality healthcare, such as early cancer screening, is a contributing factor. Check out the new study published in JAMA Internal Medicine (May 8, 2017), and check out Gx™ cancer genetic screening.
Gx™ Inherited Cancer Gene Testing (Gx™ InhCa) Analyzes 39 genes linked to breast, ovarian, colorectal, pancreatic, and other major types of cancers Early cancer screen contributes to greatly increased life expectancy in the US, according to a recent report in…